Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Verastem, Inc.

http://www.verastem.com

Latest From Verastem, Inc.

Yakult's Japan Duvelisib Decision Casts New Shadow Over Shrinking Pharma Ops

Yakult’s decision to pull an approval application for duvelisib in Japan came shortly after a FDA advisory committee said it would re-evaluate the safety and efficacy of the PI3K inhibitor four years since its approval. The developments cast a new shadow over Yakult’s already-suffering pharmaceutical business.

Commercial Japan

Finance Watch: Q1 Biopharma IPOs Shrink To A Fraction Of 2021 Total

Public Company Edition: Only nine drug developers went public in the US, raising $807m in the first quarter, versus 32 IPOs raising $5.2bn in Q1 of last year. Also, MoonLake closed its SPAC merger, Sanofi priced €650m in sustainability-linked bonds in €1.5bn note sale, and Kaleido will cease operations.

Financing Innovation

‘Dangling’ Cancer Indications In US: New Year Brings New Withdrawals Of Accelerated Approvals

Gilead pulls Zydelig’s third-line indications in follicular B-cell lymphoma and small lymphocytic lymphoma due to confirmatory trial enrollment challenges resulting from an evolving treatment landscape; 13 cancer indications now have been withdrawn since the FDA began cracking down on accelerated approvals that have not confirmed clinical benefit.

Clinical Trials Review Pathway

Did MEI/Kyowa Kirin Beat The PI3K Tolerability Trap?

PI3K-delta inhibitors have often suffered from safety and tolerability issues, but Phase II data show higher efficacy and lower discontinuation rates for zandelisib than others in the class.

Cancer Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • Other Names / Subsidiaries
    • Verastem Oncology
UsernamePublicRestriction

Register